Free tool
FAERS Monitor: Taltz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125521 or its brand name (Taltz, Ixekizumab). Reports on generic versions are filed under their own applications.
Reports
37,285
Serious
8,108
22% of reports
Hospitalization
3,067
Death reported
561
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain3,931
- psoriasis3,296
- drug ineffective3,287
- injection site erythema2,214
- injection site reaction1,798
- injection site swelling1,659
- incorrect dose administered1,199
- product dose omission issue962
- pain950
- covid-19923
- arthralgia906
- therapy interrupted845
- diarrhoea840
- rash839
- psoriatic arthropathy821
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 405 |
| 2017 | 2,073 |
| 2018 | 3,763 |
| 2019 | 4,770 |
| 2020 | 3,527 |
| 2021 | 4,001 |
| 2022 | 5,000 |
| 2023 | 4,508 |
| 2024 | 4,451 |
| 2025 | 3,435 |
| 2026 | 1,352 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,874 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site reactionSignal | 1,798 | 15.1 | 14.4 | 23,131 |
| psoriasisSignal | 3,296 | 14.6 | 14.1 | 40,874 |
| injection site swellingSignal | 1,659 | 12.5 | 11.9 | 17,163 |
| psoriatic arthropathySignal | 821 | 11.6 | 10.9 | 7,816 |
| injection site erythemaSignal | 2,214 | 10.2 | 9.8 | 18,214 |
| injection site painSignal | 3,931 | 7.3 | 7.1 | 21,444 |
| therapy interruptedSignal | 845 | 6.7 | 6.3 | 4,088 |
| covid-19Signal | 923 | 3.0 | 2.8 | 1,215 |
| incorrect dose administeredSignal | 1,199 | 3.0 | 2.8 | 1,577 |
| product dose omission issue | 962 | 1.8 | 1.7 | 378 |
| drug ineffective | 3,287 | 1.4 | 1.4 | 413 |
| arthralgia | 906 | 1.2 | 1.2 | 39 |
| rash | 839 | 1.1 | 1.0 | 6 |
| pain | 950 | 0.9 | 0.8 | 18 |
| diarrhoea | 840 | 0.7 | 0.7 | 83 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.